Acrolein, a molecule implicated as a metabolic waste product, could be a potential biomarker for multiple sclerosis, researchers report.
Findings suggest a possible new diagnostic tool for early detection and treatment of blast related TBI.
Researchers adapt a medical test, previously developed to measure a toxin found in smokers, to measure the same toxin in people suffering from MS and spinal cord injuries.
